Replies to post #87704 on Biotech Values

[DewDiligence]

…reversibility could help either branded or generic Lovenox compete against the newer oral anti-coagulants, correct?

Maybe, but I’m skeptical—I think PYMX is exaggerating the relevance of Lovenox reversibility, especially on the venous side (where most of Lovenox’s business comes from).

Moreover, the point of #msg-44647627—that SNY and NVS will be disinclined to help their competitor—stands independently of whether reversibility of Lovenox is a significant medical need. I’ve never seen a case where a drugmaker inks a development partnership for an adjunct to a drug that’s already gone generic. I suppose PMX-60056 could be the first, but I wouldn’t count on it.

If the FDA ended up rejecting all of the Lovenox ANDA’s, the business impetus for SNY to partner with PYMX would naturally go up. Hopefully (for MNTA investors), this is not going to happen.